- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia.
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 390KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 63KB)
Alirocumab – March 2023
Alirocumab: Injection 300 mg in 2 mL single dose autoinjector; Praluent®
Last updated
30 June 2023